

Serious Adverse Event Reporting
ANRS 12249 Initial SAE Notification

Completed forms must be sent to
ANRS within 48 hrs.
Email: pharmacovigilance@anrs.fr
Fax: +33 153 946 002



00317417

SAE No.

SAE Visit Date

Initial Notification Date 20150904 Notification time 0930

1. Patient details

TasP ID

13639

Name

G. H.

Sex

Male

☒ Female

Date of birth

19630309

Enrolment date

20120405

2. Measurements

Height

160

Cms

Last known: Weight

48

Kgs

Weight Date

20150813

CD4 count

225

CD4 Date


20150727

Viral Load

113

Viral Load Date

20150727


3. By which criteria is this adverse event considered to be "Serious"?

Tick all that apply

- ☐ Resulted in death → Date of death Probable cause
- ☐ Life threatening (i.e. at risk of death at time of event)
- ☐ Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)
- ☐ Persistent or significant disability / incapacity
- ☐ Congenital abnormality / birth defect
- ☒ Grade 4 clinical and biological events
- ☐ Other serious, medically-important condition → Specify

4. Details of SAE

Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name
Date investigator
became aware
Date of onset of SAE

1. elevated Gamma-glutamyl transaminase 20150901 20150727

2.

3.

4.

5.

5. Description of SAE

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.

Attach copies of any relevant hospital records, laboratory test results etc.

Participant in control arm of trial. On Atazanavir with CD4 count 225 & viral load 113. On routine review of blood results, her GGT was 1513, ALP 145 and ALT 42. She has a strong history of alcohol abuse and blood results may be attributed to cholestasis secondary to alcohol abuse. She has been advised to reduce alcohol intake & is being monitored.

6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

	Generic Name	Daily dose	Route of administration	Indication	Date started	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
					Date stopped			
1.	Tenofovir	300mg	oral	HIV	20150625	<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2.	Emtricitabine	200mg	oral	HIV	20150625	<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3.	Efavirenz	600mg	oral	HIV	20150625	<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop

7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research?

Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research?

This includes the patient's medical history

☒ Yes ☐ No

Describe

Participant has history of alcohol abuse which is likely to account for raised liver enzymes.

8. SAE Outcome

Died

Unknown to date

☒ Ongoing

Improved

Recovered

→ A complementary SAE notification must be submitted within 8 days

→ Date of recovery

Recovered without sequelae

or

Recovered with sequelae

Describe

Physician reporting SAE

Name GUG'ELIHE MUKHULISI

Signature

Date form completed 20150904